EUCTR2007-005422-76-DE进行中（未招募）不适用
Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An open label, stratified, single-arm phase II study of Bevacizumab and RAD001
PD Dr. Gerhard Treiber0 个研究点开始时间: 2009年1月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age >18 years
- •2. Patients with non-resectable locally advanced or metastatic hepatocellular cancer BCLC stage B and C. BCLC stage A can occasionally be included provided that other treatment options are unavailable: they can be denied by the patient, have been performed with documented disease progression or cannot be carried out for other resons such as comorbidities
- •3. Measurable disease: At least one measurable lesion (longest diameter = 20 mm on conventional CT or MRI scan; = 10 mm on spiral CT) according to RECIST criteria that has not been previously locally treated by irradiation, surgery, ethanol injection, radiofrequency ablation or transarterial chemoembolisation. If the patient has had any previous local treatment to the marker lesion(s), there must be evidence of progression since then. The last scans should be approximately = 4 weeks old before randomisation to be used as baseline scans.
- •4. Confirmation of HCC disease by histology (preceeding liver resection or fine needle biopsy within the last 12 months);
- •5. Liver Function: Child A and B
- •6. Tumor extent: CLIP Score = 3
- •7. ECOG Performance Status 0-2 (=Karnofsky-Index = 60%)
- •8. No mental illness that prevent patients from comprehensiveness, written informed consent
- •9. Written, voluntary informed consent
- •10. Compliant patient, regular follow-up possible
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Participation in another clinical trial at the same time or = during the last 4 weeks
- •2. Patient had received any prior systemic treatment (possible exception: sorafenib for a maximum of 3 months, last dose received at least 28 days before study inclusion)
- •3. Pat. has received any other investigational agents within 28 days of first day of study drug dosing
- •4. Pat. had a major surgery, local ablative treatments (RFA, PEI), or transarterial chemoembolisation therapy within 4 weeks prior to randomisation
- •5. Pat. with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
- •6. Further, if the patient is unable to refrain from alcohol or other substance abuses or any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study
- •7. Presence of a secondary malignancy either at the time of screening or in the past 5 years: An exception from this rule can be made in patients that were treated in curative intention within the last 3 years and are without any evidence of recurrence of this malignancy.
- •8. History or presence of central nervous system disease (i.e., primary brain tumor, malignant seizures, CNS metastases or carcinomatous meningitis) or other mental illness.
- •9. Clinically serious infections or uncontrolled infection (including HIV infection), increased risk for acquisition of opportunistic infections
- •10. Chronic treatment with systemic steroids or another immunosuppressive agent; interactions with other drugs interfering with the CYP3A4 system should be avoided but can be permitted under circumstances of clinical need and close patient monitoring, provided that the medication used will be kept constant over the first 24 weeks of treatment
- •11. Indequate organ functions, characterised by: cholestasis with elevated levels of bilirubin and/or alkaline phosphatase > 3x UNL (can be improved by biliary drainage if necessary) and/or elevated transaminases (ALAT/ASAT) = 5 x UNL, hypoalbuminemia < 2.5 g/dl, renal impairment (serum creatinine < 1.5 x UNL ), inadequate Hematology: Platelets < 75.000, ANC < 1500, hemoglobine < 9.0 mg/dl, inadequate coagulation status, namely INR > 2 or Quick < 50%, aPTT >50 sec in the absence of any drugs interfering with coagulation such as warfarin, phenprocoumone, NMH or UFH. Low-dose aspirin up to 100 mg/d or clopidogrel up to 75 mg/d are permitted together with obligatory prophylactic proton-pump-inhibitor treatment; Fasting serum cholesterol =300 mg/dL OR 7.75 mmol/L AND fasting triglycerides = 2.5 x ULN, patients with severe refractory therapy-resistant hyperlipidemia
- •12. Women who are pregnant or breast feeding, intended pregnancy, or women unable to conceive and unwilling to practice an effective method of birth control. (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001). Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study
- •13. Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of RAD001 and cannot be controlled by adequate medical treatment (e.g. uncontrolled nausea, vomiting, diarrhoea which might result in malabsorption, any known malabsorption syndrome, bowel obstruction, or inability to swallow the tablets)
- •Criteria derived from special situations:
研究者
相似试验
进行中（未招募）
不适用
ow-dose Cytotoxics as Anti-angiogenesis Treatment” following AdjuvantInduction Chemotherapy for Patients with ER-negative and PgR-negativeBreast CancerMaintenance Chemotherapy in Hormone Non- Responsive Breast Cancer - Maintenance Chemotherapy in Hormone Non-Responsive Breast CancerHistologically proven ER-negative and PgRnegative breast cancer with either a total mastectomy with axillary clearance or a lesser procedure with axillary lymph node dissection or sentinel node procedure, and classified as T1a,b,c, T2, T3, or pT4 with minimal dermal invasion, Nx, pN0, pSentN0, pN1, or pN2, and M0. Patients with disease defined as SNB positive are eligible only if they have undergone an axillary dissection, OR are SNB micrometastatic and are randomized to IBCSG Trial 23-01.MedDRA version: 9.1Level: LLTClassification code 10006190Term: Breast cancer invasive NOSEUCTR2005-005666-36-SEInternational Breast Cancer Study Group1,080
进行中（未招募）
不适用
Treatment of locally advanced or metastatic non-small cell lung cancer with Pemetrexed (Alimta) and Gemcitabine or Gemcitabine and Carboplatin: The PAGe study. - The PAGe studyEUCTR2005-001577-97-SEGunnar Hillerdal96
进行中（未招募）
不适用
Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer – a dose finding studyadvanced and/or metastatic pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticEUCTR2006-003403-39-DEovartis Pharma GmbH
终止
2 期
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast CancerChemotherapyBreast Cancer, MetastaticNCT01067989HaEmek Medical Center, Israel22
已完成
3 期
MATES: Maintenance Thalidomide in Mesothelioma Patients. A phase III trial of anti-angiogenic agent Thalidomide in patients with malignant pleural mesothelioma after first line chemotherapy.ACTRN12609000141246niversity of Sydney14